Application of chebulal preparation in preparation of medicine for treating TgAb injury of human thyroid follicular cells

The prepared chebula preparation alleviates TgAb-damaged thyroid follicular cells, solving the problem of insufficient universality and efficacy of traditional Chinese medicine in the treatment of Hashimoto's thyroiditis, and achieving the protection and repair of thyroid follicular cells.

CN118987060AActive Publication Date: 2024-11-22HENAN UNIV OF CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411075842.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

Existing TCM treatments for Hashimoto's thyroiditis (HT) suffer from problems such as excessive syndrome differentiation, large differences in prescription combinations, and a lack of universality. Furthermore, TgAb-based drugs that damage thyroid follicular cells are not effective enough.

Method used

The drug was prepared using Terminalia chebula preparations through steps such as soaking, decocting, concentration, centrifugation, drying and freezing, with a concentration of 46.93 μg/mL, and was used to treat TgAb-damaged human thyroid follicular cells.

Benefits of technology

It alleviates TgAb-induced inhibition of thyroid follicular cell proliferation, apoptosis, cell migration, and overexpression of inflammatory factors, regulates thyroid hormone levels, and effectively treats Hashimoto's thyroiditis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987060A_ABST
    Figure CN118987060A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines. According to the application of the chebulal preparation in preparation of the medicine for treating the TgAb-injured human thyroid follicular cells, the protection effect on a TgAb-induced cell injury model is gradually enhanced along with increase of the concentration of the chebulal preparation, and injuries such as TgAb-induced Nthy-ori3-1 cell proliferation inhibition, apoptosis, cell migration and inflammatory factor overexpression can be relieved; regulating the secretion level of T4; meanwhile, the thyroxine level is adjusted, a foundation is laid for research of a thyroid injury mechanism, and a treatment basis is provided for application of traditional Chinese medicine in hashimoto thyroiditis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to application of a terminalia chebula preparation in preparing a medicine for treating TgAb-damaged human thyroid follicular cells. Background Art

[0002] Hashimoto thyroiditis (HT) is an autoimmune thyroid disease characterized by lymphocyte infiltration. Thyroglobulin antibodies (TgAb) and thyroid peroxidase antibodies (TPOAb) are the main thyroid autoantibodies against thyroglobulin (Tg) and thyroid peroxidase (TPO) antigens, respectively. High titers of TgAb and TPOAb in serum are the standard basis for clinical diagnosis of HT. Tg and TgAb, after the specific binding of this pair of antigens and antibodies, the Fc segment binds to the Fc receptor on the surface of NK effector cells, which can mediate killer cell damage to thyroid follicular epithelial cells. When TgAb accumulates excessively in the thyroid gland, it can lead to the hydrolysis of multiple proteins including Tg throughout the body, thereby causing damage to multiple tissues and organs throughout the body. That is, TgAb can significantly damage human thyroid follicular cells and inhibit the growth and proliferation of thyroid follicular cells.

[0003] From the perspective of traditional Chinese medicine, the key to treating HT is to control inflammation. In terms of the diagnosis and treatment of clinical diseases, although traditional Chinese medicine has definite efficacy, few toxic side effects, and is easily accepted by patients, it still has practical problems such as too many syndrome differentiations and differences in compatibility and prescription composition, and cannot provide a universal basis for guiding the use of drugs for HT in clinical practice.

[0004] Therefore, obtaining an effective traditional Chinese medicine for HT is an urgent problem to be solved in current research. Summary of the invention

[0005] The purpose of the present invention is to provide an application of a Terminalia thyroxine preparation in the preparation of a drug for treating TgAb-damaged human thyroid follicular cells. The preparation of the present invention can alleviate TgAb-induced Nthy-ori3-1 cell proliferation inhibition, apoptosis, cell migration and overexpression of inflammatory factors and other damages, regulate thyroid hormone levels, and effectively treat Hashimoto's thyroiditis.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides an application of a terminalia chebula preparation in preparing a medicine for treating human thyroid follicular cells damaged by TgAb.

[0008] Preferably, the preparation process of the terminalia chebula preparation comprises: (1) adding water to terminalia chebula in a mass volume ratio of 1 g: (15-25) mL for soaking, then decocting and concentrating to obtain a medicinal solution;

[0009] (2) The drug solution is centrifuged, dried, frozen, and crushed to obtain drug powder.

[0010] Preferably, the decoction time is 45-70 min / time, and the decoction frequency is 2-3 times.

[0011] Preferably, the centrifugation time in step (2) is 15-30 min, and the centrifugation speed is 2000-4000 rpm.

[0012] Preferably, the drying time in step (2) is 23-26 hours; and the freezing time is 10-14 hours.

[0013] Preferably, the concentration of the Myrobalan preparation is 25-50 μg / mL.

[0014] By adopting the above technical solution, the present invention has the following beneficial effects:

[0015] The terminalia preparation described in the technical solution of the present invention mainly includes the medicinal flavor of terminalia, and the terminalia preparation is used at a concentration of 46.93 μg / mL, which can improve the damage of TgAb to thyroid follicular cells, alleviate TgAb-induced Nthy-ori3-1 cell proliferation inhibition, apoptosis, cell migration and overexpression of inflammatory factors, and regulate T4 secretion levels. Experiments have shown that the terminalia preparation described in the present invention can alleviate the migration of damaged thyroid follicular cells, accelerate the disappearance of inflammation, and facilitate the development of tissue regeneration and repair; it can alleviate the inflammatory damage caused by overexpression of the inflammatory factor IL-6 in the thyroid follicular cell injury model, and regulate the secretion level of T4; it can also regulate the level of thyroxine and effectively alleviate thyroid damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 The dose-effect relationship diagram of the protective effect of the Herba Cibotii preparation on normal cells and cell injury models ( Figure 1 A is the protection rate for normal cells, and B is the protection rate for cell damage model);

[0017] Figure 2 The results of migration ability of thyroid follicular cell injury model in different groups;

[0018] Figure 3 The migration ability of thyroid follicular cells in different groups ( Figure 3 A is the cell migration of the model control group at 0 h, B is the cell migration of the model control group at 24 h, C is the cell migration of the model medication group at 0 h, and D is the cell migration of the model medication group at 24 h);

[0019] Figure 4The morphological changes of thyroid follicular cells in different groups under an inverted phase contrast microscope ( Figure 4 A is the blank control group, B is the model control group, C is the blank treatment group, and D is the model treatment group);

[0020] Figure 5 The apoptosis of thyroid follicular cells in different groups;

[0021] Figure 6 The contents of T4 and IL-6 in thyroid follicular cells of different groups ( Figure 6 A is T4 content, B is IL-6 content). DETAILED DESCRIPTION

[0022] The present invention provides an application of a terminalia chebula preparation in preparing a medicine for treating human thyroid follicular cells damaged by TgAb.

[0023] In the present invention, the raw material components in the terminalia preparation mainly include terminalia. Terminalia described in the present invention is also known as terminalia, which is bitter, sour, astringent and warm in nature, has the functions of astringing the lungs, astringing the intestines and lowering the qi, and its effective components mainly include tannin phenolic acids, triterpenes and polysaccharides. Modern pharmacological studies have shown that terminalia has multiple pharmacological effects such as anti-oxidation, lowering blood sugar and blood lipids, resisting pathogenic microorganisms, inhibiting bacteria and anti-inflammatory, analgesic and anti-tumor, and also has a two-way regulatory effect on the body's immune function; terminalia extract can reduce serum pro-inflammatory factor IL-6.

[0024] In the present invention, the weight proportion of the terminalia chebula is preferably 25-35 parts, more preferably 28-33 parts, and even more preferably 30 parts.

[0025] In the present invention, the preparation process of the terminalia chebula preparation comprises: (1) adding water to terminalia chebula in a mass volume ratio of 1 g: (15-25) mL for soaking, then decocting and concentrating to obtain a medicinal solution;

[0026] (2) The drug solution is centrifuged, dried, frozen, and crushed to obtain drug powder.

[0027] In the present invention, water is added to the terminalia chebula for soaking. The water added in the present invention is preferably ultrapure water, and the mass volume ratio of the terminalia chebula to water is preferably 1 g: (15-25) mL, more preferably 1 g: (17-22) mL, and more preferably 1 g: 20 mL. The soaking time in the present invention is preferably 20-35 min, more preferably 25-33 min, and more preferably 30 min.

[0028] In the present invention, the terminalia chebula is directly decocted together with the immersion water after the soaking, and the decoction method is preferably to first heat to boiling with high heat, and then adjust to slow heat to continue decocting. The decoction time of the present invention is preferably 45-70min / time, further preferably 50-64min / time, and further preferably 55min / time; the number of decoctions is preferably 2-3 times, and further preferably 2 times. Preferably, stirring is performed during the slow-heat decoction in the present invention; filtering is performed after the slow-heat decoction is completed, the medicinal residue is separated, the filtrate is collected, and then the filtrate is combined. In the present invention, the second decoction is preferably slow-heat decoction; the amount of water added during the second decoction is preferably (6 / 24) to (12 / 24) times of the amount of water added during the soaking, further preferably (9 / 24) to (11 / 24) times, and further preferably 10 / 24 times. In the present invention, the purpose of the second decoction is to precipitate the remaining effective ingredients of the Chinese medicine composition to the maximum extent.

[0029] In the present invention, the filtrate is concentrated to obtain a medicinal solution, and the degree of concentration is preferably a volume ratio of the medicinal solution to the amount of water added during immersion of 1:(8-14), further preferably 1:(9-12), and further preferably 1:10.

[0030] In the present invention, the obtained medicinal solution is subjected to a centrifugal operation, and the centrifugal operation is preferably performed using a low-temperature high-speed centrifuge. The centrifugal time is preferably 15-30 min, further preferably 23-28 min, and further preferably 25 min; the centrifugal speed is preferably 2000-4000 rpm, further preferably 2800-3500 rpm, and further preferably 3000 rpm.

[0031] In the present invention, drying is preferably performed after the centrifugal operation, and the drying method is vacuum drying; the drying time is preferably 23-26 hours, more preferably 23.5-25 hours, and further preferably 24 hours.

[0032] In the present invention, after vacuum drying, freeze drying is performed to obtain a crystalline powder, and the freeze drying temperature is preferably -(18-25)°C, more preferably -(19-22)°C, and more preferably -20°C; the freeze drying time is preferably 10-15h, more preferably 11-13h, and more preferably 12h. In the present invention, the obtained crystalline powder is crushed to obtain the medicinal powder.

[0033] In the present invention, the obtained Herba Terminaliae powder is mixed with a solution in a mass volume ratio of 1 g: (0.2-0.3) mL, and the Herba Terminaliae liquid is obtained by filtration. The solution in the present invention is preferably RPMI-1640 culture medium; the mass volume ratio of the mixture is further preferably 1 g: (0.22-0.28) mL, and further preferably 1 g: 0.25 mL. The filtration in the present invention is preferably carried out using a bacterial filter membrane, and the specification of the filter membrane is preferably 0.22 μm. The bacterial filter membrane in the present invention is purchased from Merck Millipore, USA.

[0034] In the present invention, the concentration of the terminalia chebula preparation is preferably 25-50 μg / mL, more preferably 35-48 μg / mL, and even more preferably 46.93 μg / mL.

[0035] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0036] Example 1

[0037] Application of the Herba Terminaliae chebulae preparation in the preparation of a drug for treating TgAb-damaged human thyroid follicular cells, the application method being:

[0038] (1) Take 30 g of Terminalia chebula and add 600 mL of ultrapure water to soak for 30 min, then place on an electric stove covered with asbestos mesh and heat until the water boils, then adjust to low heat and continue to decoct for 55 min, filter and separate the residue, and collect the filtrate; add 250 mL of ultrapure water to the residue for a second decoction, decoct for 55 min, filter again, collect the filtrate, and combine the filtrate; then concentrate to a volume of 60 mL to obtain a medicinal solution;

[0039] (2) The obtained drug solution was centrifuged at 3000 rpm for 25 min, then vacuum dried for 24 h, covered with plastic wrap, and freeze-dried at -20°C for 12 h to obtain crystalline powder, which was crushed to obtain drug powder;

[0040] (3) The obtained Myrobalan powder was mixed with RPMI-1640 culture medium at a ratio of 1 g:0.25 mL, and then filtered through a 0.22 μm bacterial filter membrane to obtain the obtained product.

[0041] Example 2

[0042] Application of the Herba Terminaliae chebulae preparation in the preparation of a drug for treating TgAb-damaged human thyroid follicular cells, the application method being:

[0043] (1) Take 30 g of Terminalia chebula and add 450 mL of ultrapure water to soak for 20 min, then place on an electric stove covered with asbestos mesh and heat until the water boils, then adjust to low heat and continue to decoct for 45 min, filter and separate the residue, and collect the filtrate; add 112.5 mL of ultrapure water to the residue for a second decoction, and after the second decoction for 45 min, filter again, collect the filtrate, and combine the filtrate; then concentrate to a volume of 56.25 mL to obtain a medicinal solution;

[0044] (2) The obtained drug solution was centrifuged at 2000 rpm for 23 min, then vacuum dried for 24 h, covered with plastic wrap, and freeze-dried at -19°C for 12 h to obtain crystalline powder, which was crushed to obtain drug powder;

[0045] (3) The obtained Myrobalan powder was mixed with RPMI-1640 culture medium at a ratio of 1 g:0.2 mL, and then filtered through a 0.22 μm bacterial filter membrane to obtain the obtained product.

[0046] Example 3

[0047] Application of the Herba Terminaliae chebulae preparation in the preparation of a drug for treating TgAb-damaged human thyroid follicular cells, the application method being:

[0048] (1) Take 30 g of Terminalia chebula and add 750 mL of ultrapure water to soak for 35 minutes, then place it on an electric stove covered with asbestos mesh and heat until the water boils, then adjust the heat to low and continue to decoct for 64 minutes, filter and separate the residue, and collect the filtrate; add 375 mL of ultrapure water to the residue for a second decoction, and after the second decoction for 64 minutes, filter again, collect the filtrate, and combine the filtrates; then concentrate to a volume of 53.57 mL to obtain a medicinal solution;

[0049] (2) The obtained drug solution was centrifuged at 3500 rpm for 28 min, then vacuum dried for 24 h, covered with plastic wrap, and freeze-dried at -20°C for 12 h to obtain crystalline powder, which was crushed to obtain drug powder;

[0050] (3) The obtained Myrobalan powder was mixed with RPMI-1640 culture medium at a ratio of 1 g:0.28 mL, and then filtered through a 0.22 μm bacterial filter membrane to obtain the obtained product.

[0051] Test Example 1

[0052] 1. Cell culture

[0053] Quickly take out the cryovial of Nthy-ori3-1 cells (purchased from JENNIO Biological Technology) from the liquid nitrogen tank, put the cryovial containing 1 mL of cell suspension into a 37°C water bath to thaw, wipe the surface of the cryovial with alcohol and move it into the clean bench, add 4 mL of RPMI-1640 medium (purchased from Gibco, USA) and mix it, centrifuge at 1000 rpm for 5 min, discard the supernatant, and then blow it with 9 mL of RPMI-1640 medium, add 1 mL of FBS (purchased from Gibco, USA), move all the cell suspension into a cell culture dish, place it in a 37°C constant temperature cell culture incubator, change the medium every other day, and observe the cell growth at any time. After 1 day of cell recovery culture, observe the cell growth and change the medium. Place the cell culture dish in a clean bench and shake it crosswise to remove the cells that were not firmly attached to the wall. Aspirate the original culture medium, add 10 mL of serum-free RPMI-1640 culture medium twice in equal amounts, shake and wash, add 10 mL of complete culture medium containing 15% FBS, and place in an incubator for culture.

[0054] (II) MTT assay

[0055] The terminalia chebula preparation prepared in Example 1 was diluted in multiples with a concentration of 400 μg / mL as the maximum value, and the concentration gradients were 400 μg / mL, 200 μg / mL, 100 μg / mL, 50 μg / mL, 25 μg / mL and 12.5 μg / mL for later use.

[0056] Nthy-ori3-1 cells were observed under an inverted microscope. When the cell morphology was good and the density reached about 80%, the cells in the logarithmic growth phase were subcultured. After counting the cells, 200 μL of 1×10 4 The cells were inoculated at a concentration of 100 μL / well into a 6-well plate and cultured in a cell culture incubator for 24 h. The supernatant was then removed and the plate was washed twice with 210 μL / well PBS. The supernatant in each well was then removed (to avoid interference of the original low-level antibodies in the experiment).

[0057] The 6-well plate was divided into 4 groups from left to right: blank control group (RPMI-1640 culture medium), model control group (RPMI-1640 culture medium + TgAb), model administration group (RPMI-1640 culture medium + TgAb + Example 1 preparation), blank administration group (RPMI-1640 culture medium + Example 1 preparation), and 3 rows of duplicate wells were set in each group. Among them, 100 μL of serum-free RPMI-1640 culture medium was added to each well of the blank control group and the blank administration group, and at the same time, 100 μL of TgAb working solution with a concentration of 8 ng / mL was added to each well of the model control group and the model administration group. After the working solution of each group fully acted on the cells for 15 minutes, 100 μL of serum-free RPMI-1640 culture medium was added to each well of the blank control group and the model control group, and at the same time, 100 μL of Example 1 preparation with a concentration of 100 μg / mL was added to each well of the model administration group and the blank administration group, and the cell culture incubator was placed to continue culturing. After 24 hours of culture, the 6-well plate was taken out and placed under a microscope for observation, then transferred to a clean bench to discard the supernatant, 100 μL of 10% MTT working solution (purchased from Sigma, USA) was added to each well, and the incubator was continued for 3.5-4 hours, the MTT solution was discarded, and 150 μL of DMSO solution (purchased from Beijing Solebow Technology Co., Ltd.) was added to each well, and the plate was moved to a horizontal shaker and shaken for 20 minutes to completely dissolve the crystal violet, and the absorbance OD value at 570 nm was measured with an enzyme marker. The experiment was repeated 3 times. The cell protection rate under the action of the preparation of Example 1 in each group was calculated, and the concentration curve of the drug dose effect was made using GraphPadPrism software.

[0058] Drug protection rate of blank administration group = (blank administration group OD value - blank control group OD value) / blank control group OD value × 100%

[0059] Drug protection rate of model drug administration group = (OD value of model drug administration group - OD value of model control group) / OD value of model control group × 100%

[0060] Net protection rate of the model drug administration group = drug protection rate of the model group - drug protection rate of the blank group

[0061] Table 1 Protection rate of different groups of preparations on normal or model cells

[0062]

[0063] According to Table 1 and Figure 1 As shown, compared with the blank administration group, the cell activity protection effect of the model administration group is more obvious, that is, the Myrica chebula preparation prepared in Example 1 of the present invention can alleviate the proliferation damage of thyroid follicular cells induced by TgAb.

[0064] Test Example 2 Cell scratch test

[0065] Use a marker to mark two parallel straight lines of moderate width on the bottom of each well of the 6-well plate in advance. Normally cultured Nthy-ori3-1 cells were routinely operated according to the cell passaging steps, and 1×10 6 Cells were cultured for 24 hours to ensure that the cells covered about 90% of the bottom of the dish. A 200 μL gun tip was used to scratch each well. The gun tip was evenly applied to make it perpendicular to the thin line marked on the bottom of the dish. Two scratches were made in each well. After scratching, PBS was washed twice to wash away the cells that fell off after mechanical damage, and then PBS was removed. The model control group was added with 500 μL of serum-free RPMI-1640 medium containing TgAb at a concentration of 8 ng / mL, and 500 μL of serum-free RPMI-1640 medium was added after the antibody acted for 15 minutes. The model administration group was also first added with 500 μL of serum-free RPMI-1640 medium containing TgAb at a concentration of 8 ng / mL, and 500 μL of RPMI-1640 medium containing the chebula preparation of Example 1 at a concentration of 400 μg / mL was added after 15 minutes for culture. The cell growth was observed and photographed at 0 and 24 h, respectively, and the same scratch site was taken at each time point as much as possible. Finally, Image J software was used for analysis and calculation.

[0066] Cell migration rate = (initial area - 24h area) / initial area × 100%.

[0067] according to Figure 2 and Figure 3 It can be seen that the scratch healing rate of the model control group was 36.49±2.09%, and the scratch healing rate of the model medication group was 19.93±4.4%, indicating that the terminalia chebula preparation prepared in Example 1 of the present invention can alleviate the migration of damaged thyroid follicular cells, accelerate the disappearance of inflammation, and facilitate the development of tissue regeneration and repair.

[0068] Experimental Example 3 Observation of cell morphology using an inverted phase contrast microscope

[0069] Nthy-ori3-1 cells in the logarithmic growth phase were digested with 0.25% EDTA-containing trypsin solution, and after counting the cells, they were diluted to a cell density of 5×10 5After the cell suspension of cells / mL was inoculated in a 6-well plate, the supernatant in the well plate was sucked off and washed twice with PBS solution. Four groups of blank control group, model control group, model administration group and blank administration group were set. While 500 μL of serum-free RPMI-1640 culture medium was added to each well of the blank control group and the blank administration group, 500 μL of TgAb working solution at a concentration of 8 ng / mL was added to each well of the model control group and the model administration group. After the action time was 15 min, 500 μL of serum-free RPMI-1640 culture medium was continued to be added to each well of the blank control group and the model control group, while 500 μL of RPMI-1640 culture medium containing the cerulean preparation of Example 1 at a concentration of 400 μg / mL was added to each well of the blank administration group and the model administration group. After the 6-well plate was placed in a constant temperature incubator and continued to be cultured for 24 hours, it was transferred to an inverted phase contrast microscope to observe the morphological changes of each group of cells and magnified to 200 times for photographing and recording.

[0070] Apoptosis of thyroid cells has an atypical thyroid follicle morphology, and the differences in each stage can be obtained from morphological observation: first, the cells shrink, the connections disappear, and they detach from the adjacent cells; then the cell permeability changes, the mitochondrial membrane potential decreases, cytochrome C is released into the cytoplasm, the nucleoplasm condenses, the nuclear membrane and nucleolus are broken, and the DNA is fragmented; the cell membrane has vesicles (blistering), and the phosphatidylserine on the inner side of the membrane is everted and moved to the cell membrane surface, at this time the cell membrane structure is still intact; finally, apoptotic bodies are formed, no contents overflow, and the cytoskeleton disintegrates.

[0071] The results are as follows Figure 4 As shown in the figure, compared with the blank control group, the cell gaps in the blank administration group were wider, but the edges were clear and the growth was good. Compared with the model control group, there were more cell vacuoles in the model administration group, and the cells were easy to aggregate into clumps with blurred edges. Compared with the blank administration group, the cell boundaries in the model administration group were unclear, the edges were blurred, the cytoplasm was less, there were bubble-like cell structure protrusions, and cell fragments were visible.

[0072] Experimental Example 4 Flow Cytometry

[0073] After observing the status of Nthy-ori3-1 cells under a microscope, the cell subculture step was performed, the cells were centrifuged and counted, and 1 mL of the medium containing 1×10 6Cells were added to each well of a 6-well plate, a small amount of fetal bovine serum was added to each well, and the 6-well plate was gently shaken, placed in a constant temperature incubator for 24 hours, and then the cells were observed, and then shaken and cleaned with PBS, and then a blank control group, a model control group, and a model administration group were set up. While 500 μL of serum-free RPMI-1640 culture medium was added to each well of the blank control group, 500 μL of TgAb working solution at a concentration of 8 ng / mL was added to each well of the model control group and the model administration group. After the action time was 15 minutes, 500 μL of serum-free RPMI-1640 culture medium was continued to be added to each well of the blank control group and the model control group, and 500 μL of RPMI-1640 culture medium containing the chebula preparation of Example 1 was added to each well of the model administration group at a concentration of 400 μg / mL.

[0074] After the 6-well plate was transferred to an incubator and cultured for 24 h, the cells were washed once with PBS according to the instructions of the Annexin V-FITC apoptosis detection kit (purchased from Hangzhou Lianke Biotechnology Co., Ltd.), and the cells were digested with an appropriate amount of EDTA-free trypsin digestion solution (EDTA may affect the binding of Annexin V to phosphatidylserine). The digestion was terminated, the cells were gently blown and centrifuged at 2000 rpm for 5 min to collect the cells, the supernatant was discarded, and the cells were resuspended twice in 4 mL of precooled PBS. The cells were counted and collected (1-10)×10 5 cells, centrifuge again and discard the supernatant, resuspend each group of cells in 500 μL of 1×Binding Buffer into flow tubes, add 5 μL of AnnexinV-FITC dye to each tube, store at room temperature in the dark for 5 minutes after resuspending, add 10 μL of PI to each tube, gently flick to mix, incubate at room temperature in the dark for 5 minutes, and detect cell apoptosis rate by flow cytometer within 1 hour. Finally, use Flow Jo software to analyze the apoptosis results.

[0075] Table 2 Cell activity and apoptosis in different groups

[0076]

[0077]

[0078] The results are shown in Table 2 and Figure 5 As shown, compared with the blank control group, the cell apoptosis rate in the model control group was significantly increased, indicating that TgAb did induce excessive apoptosis of thyroid follicular cells; the cell apoptosis rate in the model medication group was relatively low, indicating that after medication intervention, the number of living cells can be increased and the occurrence of cell apoptosis can be alleviated.

[0079] Test Example 5 Enzyme-linked immunosorbent assay

[0080] After Nthy-ori3-1 cells were subcultured according to the procedure, 1 mL of 1×10 6 Cells were added to each well of a 6-well plate, a small amount of fetal bovine serum was added to each well, and the 6-well plate was gently shaken, placed in a constant temperature incubator for 24 hours, and then the cells were observed, and then shaken and cleaned with PBS, and then a blank control group, a model control group, and a model administration group were set up. While 500 μL of serum-free RPMI-1640 culture medium was added to each well of the blank control group, 500 μL of TgAb working solution at a concentration of 8 ng / mL was added to each well of the model control group and the model administration group. After the action time was 15 minutes, 500 μL of serum-free RPMI-1640 culture medium was continued to be added to each well of the blank control group and the model control group, and 500 μL of RPMI-1640 culture medium containing the chebula preparation of Example 1 was added to each well of the model administration group at a concentration of 400 μg / mL. Then transfer the 6-well plate to an incubator and culture for 24 hours. Take the cell supernatant and transfer it to 2 mL EP tubes. Centrifuge at 2500 rpm for 20 minutes at 4°C. Then pipette the supernatant into a new spare EP tube as a sample for subsequent experiments or store it in a -80°C refrigerator.

[0081] Before the experiment officially begins, place the ELISA kit at room temperature for 30 minutes. Then follow the instructions in the relevant manual to operate in accordance with the instructions. Use the corresponding detection reagents for human thyroxine (T4) and inflammatory factors (IL-6), and do not confuse them. Set up blank wells, standard wells, and sample wells to be tested, dilute and add concentrated washing solution and standard samples, and then (incubate and wash) add enzyme label reagent except blank wells, incubate and wash, add colorimetric reagent and mix, keep in dark at 37°C for 15 minutes, stop the reaction with stop solution, and finally adjust the blank well to zero. Within 15 minutes, quickly detect the absorbance OD value at a wavelength of 450nm. Then, according to the known concentration of the standard and the detected OD value, use Excel software to calculate the linear regression equation and calculate the sample concentration, and use GraphPad Prism8 software for statistical analysis. The results are shown in Table 3-4.

[0082] Table 3 T4 content in cell supernatant of different groups

[0083]

[0084]

[0085] Table 4 IL-6 content in cell supernatants of different groups

[0086] Group IL-6 content (ng / L) Blank control group 120.4±13.88 Model control group 160.32±2.99 Model drug group 117.55±5.04

[0087] From Table 3-4 and Figure 6It can be seen that in terms of T4 content, the T4 content in the model administration group is higher than that in the model control group and lower than that in the blank control group; while the content of the inflammatory factor IL-6 in the model administration group is lower than that in the model control group. This indicates that the Myrobalan preparation prepared in Example 1 of the present invention can effectively alleviate the inflammatory damage caused by overexpression of the inflammatory factor IL-6 in the thyroid follicular cell injury model and regulate the secretion level of T4.

[0088] From the above embodiments and test examples, it can be seen that the optimal concentration of the terminalia chebula preparation prepared by the technical solution of the present invention is 46.93 μg / mL. The use of this preparation can alleviate the migration of damaged thyroid follicular cells, accelerate the disappearance of inflammation, and facilitate the development of tissue regeneration and repair; it can alleviate the inflammatory damage caused by the overexpression of the inflammatory factor IL-6 in the thyroid follicular cell injury model, and regulate the level of T4 secretion; it can also regulate the level of thyroxine and effectively alleviate thyroid damage.

[0089] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of Herba Terminaliae preparations in the preparation of drugs for treating TgAb-damaged human thyroid follicular cells.

2. The use according to claim 1, characterized in that: The preparation process of the terminalia chebula preparation comprises: (1) adding water to terminalia chebula in a mass volume ratio of 1 g: (15-25) mL for soaking, then decocting and concentrating to obtain a medicinal solution; (2) The drug solution is centrifuged, dried, frozen, and crushed to obtain drug powder.

3. The use according to claim 1, characterized in that: The decoction time is 45-70 min / time, and the decoction frequency is 2-3 times.

4. The use according to claim 1, characterized in that: The centrifugation time in step (2) is 15-30 min, and the centrifugation speed is 2000-4000 rpm.

5. The use according to claim 1, characterized in that: The drying time in step (2) is 23-26 hours; the freezing time is 10-14 hours.

6. The use according to claim 1, characterized in that: The use concentration of the terminalia chebula preparation is 25-50 μg / mL.

Citation Information

Patent Citations

  • Mongolian medicine composition for treating thyroid diseases and preparation method of pill of composition

    CN110201054A

  • Application of Helile powder aqueous extract adopting golden chamber synopsis formula in preparation of drug for inhibiting esophageal cancer cells

    CN110393732A

  • Traditional Chinese medicine composition for protecting thyroid follicular cells damaged by TPOAb and application of traditional Chinese medicine composition

    CN114949087A